Clinical Trial: Recombinant vWF Concentrate and ECMO
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Bleeding Disorder
Study Type: INTERVENTIONAL
Official Title: Safety and Tolerability of Recombinant Von Willebrand Factor Concentrate in Adult ECMO Patients With Major Bleeding: A Phase I Study
Brief Summary:
Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS).Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation.This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time.The primary objectives are to evaluate the safety,…
Read more